MENU
ERAS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Erasca (ERAS) Ownership - Who owns Erasca?
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more
Profile
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
405.1M
P/E Ratio
N/A
Total Cash
304.59M
Projected Growth
N/A
Total Debt
50.81M
Revenue
N/A
Risk (Beta)
0.87
Dividend Yield
N/A
Total Cash/Share
1.08
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
ERAS
Capitalization
405M
P/E Ratio
N/A
Risk (Beta)
0.87
Dividend Yield
N/A
Total Cash
305M
Total Cash/Share
1.08
Total Debt
50.8M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
400M
P/B Ratio
1.06
Cash Flow
N/A
Earnings
-0.57
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
28K
Current Ratio
12.35
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-150.24M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-37.47
Shares Held By Institutions
364M
Shares Outstanding - Current
283M
Total Liabilities
71.7M
Total Volume MTD
N/A
Value
1
Gain YTD
-43.028
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ERAS showed earnings on May 13, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com